All In Biotech

BLA 761315 · Novo Nordisk INC

Alhemo

Concizumab-Mtci · Subcutaneous · Tissue Factor Pathway Inhibitor Antagonist

NovelPriority reviewOrphan

CDER novel approval, Dec 20, 2024: For routine prophylaxis to prevent bleeding episodes in hemophilia A and B

Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Dec 20, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

3 Phase 3, 0 recruiting

FAERS reports

45

36 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2025.

Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors • hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors Alhemo is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors • hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors ( 1 )

Mechanism: Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI). Through the inhibition of TFPI, concizumab-mtci acts to enhance FXa production during the initiation phase of coagulation which leads to improved thrombin generation and clot formation with the goal of achieving hemostasis in patients with Hemophilia A or B regardless of their inhibitor status. The effect of concizumab-mtci is not influenced by the presence of inhibitory antibodies to FVIII or FIX. There is no structural relationship or sequence homology between concizumab-mtci and FVIII...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
  • ALHEMO · CONCIZUMAB-MTCI 150MG/1.5ML(100MG/ML) · Injectable, Subcutaneous · Prescription
  • ALHEMO · CONCIZUMAB-MTCI 300MG/3ML(100MG/ML) · Injectable, Subcutaneous · Prescription
  • ALHEMO · CONCIZUMAB-MTCI 60MG/1.5ML(40MG/ML) · Injectable, Subcutaneous · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Concizumab" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemarthrosis11
  • fall4
  • condition aggravated3
  • haematoma muscle3
  • injection site pain3
  • muscle haemorrhage3
  • anti factor ix antibody increased2
  • contusion2
  • death2
  • haematoma2
  • haematuria2
  • haemorrhage2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20241
202527
202617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.